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The alp interferons (IFNs) transiently induce genes through an IFN-stimulable DNA response element (ISRE). IFN-cell surface receptor interaction 
triggers the cytoplasmic activation of the complex primary transcription factor E, which on translocation and interaction with the ISRE initiates 
transcription. Whether E is activated directly through the receptor(s) or through a more classical second message pathway(s) and the roles of ad- 
ditional factors in the a/l and y IFN responses remain to be established. Meanwhile analysis of mutants has revealed complexity and overIap in 
the GI,~ and y IFN response pathways and the products of at least two viruses have been shown to inhibit IFN-inducible gene expression. 
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1. INTRODUCTION 
At least three recent reviews on the control of in- 
terferon (IFN)-inducible gene expression are published 
or in press [l-3]. The most comprehensive is that from 
Bryan Williams whereas those from Levy and Darnell 
and Pfeffer and Tan present contrasting views as to the 
likely involvement of classical second message path- 
ways in the response to the IFNs. Levy and Darnell 
favour the direct (although possibly multistep) activa- 
tion of a transcription factor by the IFN-cell surface 
receptor complex without any requirement for classical 
second messengers, whereas Pfeffer and Tan review the 
not inconsiderable evidence for such a requirement. 
I-Iere we briefly review what is known in these areas and 
suggest a way in which these contrasting views might be 
reconciled. In addition we discuss some of our recent 
work on mutants in the IFN response pathway and the 
inhibitory effects of virus infection on the IFN 
response. 
The IFNs have profound effects on cells. They induce 
an antiviral state, can inhibit the growth of both normal 
and transformed cells and play an important role in the 
very complex cytokine network which regulates the im- 
mune system. The IFNs can be effective antiviral agents 
but their effectiveness may be limited by the ability of 
some viruses to inhibit different aspects of the IFN 
response. There are three major antigenic types of 
human IFN, (Y, ,& and y in the new terminology, leuco- 
cyte, fibroblast and immune or Type I-Q, @- an.d Type 
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II-y-IFNs in the old. The cyv P IFNs appear to interact 
with the same receptor (but see below) and induce the 
same polypeptides with similar kinetics. y-IFN interacts 
with a different receptor and induces an overlapping set 
of polypeptides with slower kinetics. For both human 
receptors, the IFN binding component has been cloned 
[4,5]. In the case of the y receptor it is accepted that 
there must be an additional signal transduction 
subunit(s). For the cy receptor(s) this is less clear-cut but 
also seems likely. 
The IFNs are effective at very low levels; only one or 
a few molecules per cell are required to trigger the an- 
tiviral response. They induce upwards of 20 genes (the 
exact number is not known) and downregulate others 
(e.g. [6]). Induction is transient, apparently involving a 
switch-off as well as a switch-on mechanism and is 
followed to a variable extent by a refractory state [7,8]. 
Over the years, different known second message signal 
transduction pathways have been implicated in the IFN 
response (e.g. [3,9-I 1 I), but as yet no consistent picture 
has emerged. (See [12] for a general review of IFN ac- 
tion.) 
2. DNA ELEMENTS 
Against this background we and others have cloned a 
number of IFN-inducible genes from human cells 
[ 14-171. Classical deletion and construct analyses have 
shown that there is a highly homologous IFN-stimul- 
able response element (ISRE) in the 5’ flanking pro- 
moter-enhancer region of these genes, for example, 
GGGAAAATGAAACT and AGGAAATAGAAACT 
for the 6-16 and 9-27 genes with which we have been 
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working. This type of ISRE is both necessary and suffi- 
cient to confer IFN inducibility [l&21,]. 
The early work was all carried cut with LY, fl IFNs and 
it was generally accepted that there would be a separate 
y IFN response element. On analysis of the 9-27 gene, 
however, it became clear that the same element is both 
necessary and sufficient to confer a y as well as an cy, p 
IFN response [22]. For the 9-27 gene the response to y 
IFN is less than that to the cy, P IFNs. Interestingly, in 
the case of a gene coding for an IFN-inducible gua- 
nylate-binding protein there is an additional response to 
y IFN that is mediated by an element overlapping the 
ISRE [23]. In contrast, several of the genes that have 
ISREs perfectly capable of conferring both LY and y IFN 
responses upon a marker gene are poorly responsive to 
y IFN when the ISRE is in its natural context. The basis 
for this is not yet clear (e.g. [ad]). It is reasonable to 
conclude, however, that while an ISRE of this type is 
both necessary and sufficient to confer a response to cy 
and y IFN, the extent to which it does so can be in- 
fluenced greatly by its context in the DNA. It remains 
possible that y IFN in particular may also have effects 
post-transcriptionally on the accumulation of induced 
messenger RNA or indeed, for example in the case of 
Class I HLAs, on the correct assembly of the protein 
products 1251. The fact that the above type of ISRE 
responds toy IFN does not, of course, mean there is not 
a different y response element governing other genes. In 
fact, there is direct evidence for this from, for example, 
the work of Strominger’s group on one of the Class II 
HLAs [26]. 
3. FACTORS INTERACTING WITH THE ISRE 
There are three types of such factors: (1) those that 
are activated very rapidly without any requirement for 
protein synthesis, for example E in our terminology 
(ISGF3 in that of Levy and Darnell); (2) those that are 
induced more slowly and require protein synthesis, for 
example M (ISGFZ) and the y IFN-inducible factor G; 
(3) constitutive factors, upon which relatively little 
work has yet been done. E can be activated within 30 
seconds in the cytoplasm of the cell in response to a, P 
IFNs and accumulates subsequently in the nucleus [27]. 
Activation of E can occur in cytoplasts excluding any 
possibility of nuclear involvement [27]. Highly purified 
E can stimulate ISRE-dependent transcription of a 
marker gene in cell-free transcription systems ([28], 
M.J. Guille, G.R. Stark and I.M. Kerr, unpublished) 
consistent with its role in initiating transcription. Levy 
and Darnell and their colleagues were the first to show 
that E is made up of at least two subunits, EQ! (ISGF3a) 
and Ey (ISGF3y) [29]. Eru, which is itself made up of at 
least 3 polypeptides [2&30] is activated by a,,5 IFNs. Ey 
is constitutive but its amount can be increased by y IFN 
at least in some cell types. Treatment of cells with a@ 
IFN results in activation of Ecu in the cytoplasm, where 
it combines with pre-existing Er to form active E. which 
on transfer to the nucleus-initiates transcription of a 
family of IFN-inducible genes (Fig. 1). Ey but not Em is 
inactivated by treatment with N-ethylmaleimide. This 
provides a basis for a convenient reconstitution assay 
for each of these two subunits [29]. Extracts from cy 
IFN-treated cells exposed to N-ethylmaleimide contain 
Ecu but not Ey, whereas extracts from control or y IFN- 
treated cells contain Ey but not active Ea. Combination 
of extracts containing Ea and Ey reconstitutes E. This 
type of assay has been used extensively in analysing the 
mutants in the IFN response pathway and in studying 
the inhibitory effects of virus infection on the IFN 
response (see below). 
It was suggested initially that ISGF2 (presumptive M) 
is a negative factor but on subsequent purification and 
sequencing [31] it proved to be identical to IRFI, a 
positively acting factor cloned by Tanaguchi et al. using 
an oligomerised oligonucleotide probe (AAGTGA)N, 
based on a sequence present in the p IFN promoter- 
enhancer region [32]. The exact role of this factor in the 
induction of p IFN per se remains controversial. To the 
extent that it has a role, however, it is clearly positive. 
Our own data 1331 are more consistent with a positive, 
INTERFERON a 
- GGAAANNGAAACT- 
a--- ISRE + 
Fig. 1. Diagrammatic representation of events in the (Y IFN response 
pathway. Much of the detail is unknown: the structure of the receptor 
complex(es), the nature of the signal transduction subunit(s), whether 
there are alternative pathways, how Ecu is activated and whether this 
activation is directly by the receptor complex or through a:~ in- 
termediary cascade, what governs transport of E to the nucleus and 
how transcription is activated on interaction of E with the ISRE, all 
remain to be established. EcY*, activated Ecu. 
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possibly maintain-on function for M @GM). In- 
terestingly, Pine et al. have shown that ISGF2 (IRFl) is 
multiply phosphorylated, but that its activity (ability to 
specifically bind an ISRE in a gel mobility shift assay) 
correlates with the absolute amount of polypeptide 
rather than its phosphorylation state [3I]. In apparent 
contrast, mutants defective in M activity appear to have 
normal amounts of (IRFI) ISGF2 polypeptide, sug- 
gesting that some post-translational modification (not 
necessarily phosphorylation) or additional component 
may bc required for activity (M.J. Guille, R. McKen- 
dry, G.R. Stark and I.M. Kerr, unpublished). Some of 
our own more recent data suggest that M is complex 
and does not simply equal IRFl. 
isolate mutants. but the most advanced involves the use 
So far we, and others, have defined a DNA element, 
the ISRE, that is both necessary and sufficient for the 
IFN response of many genes and have identified a 
number of factors through which activation of the 
ISRE is modulated by the IFNs. There is, however, 
much that we do not know. For example, how is E ac- 
tivated? Cytoplasmic activation of the transcription 
factor NFHB in response to a number of agents involves 
its release from a complex with an inhibitory subunit 
[34,35]. It is tempting to speculate that a similar mech- 
anism might be involved in the activation of E, but to 
date no evidence has been obtained for the presence of 
such an inhibitory subunit. Activation could involve 
direct interaction of a component(s) of Ecu with the 
receptor complex, or there could be a whole cascade of, 
for example, intermediate kinase reactions involved in 
the response pathway. It is not clear how to reconcile 
the relatively straightforward direct activation model 
with the apparent requirement for more classical second 
messengers [3]. One possibility that retains the attrac- 
tive specificity of direct activation but allows for a 
classical second messenger equirement is that the latter 
is needed to maintain one or more components in the 
direct pathway in an IFN-responsive state. The avail- 
ability of a cell-free system in which it is possible to ob- 
tain activation of E should greatly facilitate the further 
investigation of these early events. 
While there is much still to be discovered concerning 
the nature of E and its activation, we know less about 
the roles of M (ISGFZ) and G. Nor do we know how 
transcription is shut-off or how a refractory state is 
established. We also know a great deal less with respect 
to downregulated genes and the y IFN response, despite 
the very recent report of a factor (GAF) which may 
function prior to G in the latter pathway [36]. 
4. MUTANTS IN THE IFN RESPONSE 
Against this background much of our own recent ef- 
fort has been devoted to isolating mutants in the cu,p 
and y IFN response pathways and to studying the ef- 
fects of viral infection upon the IFN response. A 
number of different approaches are being employed to 
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of an IFN-inducible drug-selectable marker. The highly 
IFN-inducible 6-16 promoter was placed 5’ of a 
bacterial guanine phosphoribosyl transferase (gpt) gene 
in a suitable construct and transfected into hypoxan- 
thine phosphoribosyl transferase negative human 
HT1080 cells. The isolation of a clone of cells in which 
expression of gpt is strictly regulated by IFN has permit- 
ted the selection, after mutagenesis, of mutants con- 
stitutive or defective in the IFN response [37]. The abili- 
ty to select in both directions is facilitating downstream 
transfection experiments with cDNA and genomic 
libraries to rescue the mutants and isolate the genes 
responsible. We will be concerned here, however, only 
with two mutants defective in the IFN response. 
The first, coded 11 ,I, is defective in cr but not y IFN- 
inducible gene expression. The defect is likely to be 
proximal to the cy IFN receptor, possibly in a signal 
transduction subunit or in a factor or factors interac- 
ting with such a subunit. Consistent with this, mutant 
11,l is defective in activation of the Ea, subunit of the 
early transcription factor E ([37], R. McKendry, J. 
John, I.M. Kerr and G.R. Stark, unpublished). The cy 
and ,~3 IFNs share a common receptor and induce the 
same proteins with similar kinetics. It was unexpected 
therefore to find that I 1,l retains a partial response to 
,L? IFN [37]. This suggests either that there is a separate 
minor ,8 IFN receptor or that fl IFN interacts sufficient- 
ly differently with the CY receptor(s) for the activity to be 
maintained in mutant cells. 
A second mutant, U2 is also defective in the response 
to (;Y IFN for al1 of the genes tested. In contrast to ll,l, 
however, activation of the Ea subunit of E is normal in 
U2, the defect is in the synthesis or activation of the Ey 
subunit. Interestingly, again in contrast to 1 1 ,1, U2 is 
partially defective in the response to y IFN. This is 
manifest in three ways. First, the response of the 9-27 
gene to y IFN is defective (although the response of 
several other genes to y IFN is normal). Second, U2 has 
a markedly reduced antiviral response to y IFN. Third, 
U2 is defective in the induction of the y IFN-inducible 
factor G. Instead, in gel mobility shift assays, a novel y 
IFN-inducible complex that migrates more rapidly than 
that containing G is observed (J. John, R. McKendry, 
I.M. Kerr and G.R. Stark, unpublished). 
Overall therefore, these and additional mutants are 
proving valuable, not only as tools with which ultimate- 
ly to clone genes in the signal transduction pathways, 
but also in revealing complexity in and unexpected 
overlap between the a, ,8 and y IFN response pathways. 
5. EFFECTS OF VIRUS INFECTION 
It has become increasingly clear that hardly surpris- 
ingly, viruses fight back. They do so at a number of 
levels and one of these, for hepatitis B virus and 
adenoviruses, is to inhibit IFN-inducible gene expres- 
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sion. When each of the known open reading frames of tion factor E is inhibited whereas with ElA it, is the pro- 
duction or activation of the Ey subunit that is inhibited. 
It will be of considerable interest to determine the 
biochemical basis for these inhibitions. It will, of 
course, also be of interest and of clinical importance to 
determine how widespread and various are the mechan- 
isms employed by different viruses to counter the pro- 
duction of and response to the IFNs. 
hepatitis & virus was assayed for the ability to inhibit 
IFN-inducible expression of a 6-16 promoter-enhancer 
driven marker construct, only the viral polyrnerase con- 
struct was found to be inhibitory. Consistent with this, 
cells stably transfected with the polymerase gene chow- 
ed a much diminished response of the endogenous 6-l 6 
and 9-27 genes to cy and y IFNs, assayed at the level of 
inducible messenger RNAs. So far, the inhibitory effect 
of the poIymerase has been narrowed down to the ter- 
minal protein domain. The detailed mechanism of the 
inhibition is not known but the defect is in the produc- 
tion or activation of the EO subunit of the IFN- 
inducible transcription factor E [38]. The induction of 
Class I and II HLAs by the IFNs is also inhibited in 
these cells. It is possible that such inhibition, particular- 
ly of the Class 1 HLAs by the expression of polymerase 
or terminal protein might be of clinical importance in 
establishing and maintaining chronic infection. In addi- 
tion the inhibitory effect of constitutive expression of 
terminal protein operates on the production of the IFNs 
as well as the response to them. There is no induction of 
the B IFN gene in response to double-stranded RNA in 
cells expressing terminal protein [38]. 
The adenoviruses are amongst the more IFN-resiStant 
viruses and, for the moment, are the example par ex- 
cellence of viruses which appear capable of inhibiting 
the IFN response at more than one level. The role of VA 
RNA in inhibiting the IFN and double-stranded RNA- 
dependent protein kinase is well documented [39-411. 
In addition, however, Anderson and Fennie [42] show- 
ed that mutants defective in ElA showed a reduced 
ability to inhibit IFN action and an inhibitory effect of 
ElA on IFN-inducible gene expression was reported by 
Reich et al. [43]. ElA is an immediate early gene. When 
it is transcribed very early post-infection, it yields 12 S 
and 13 S mRNAs and the corresponding polypeptides. 
Three regions of these polypeptides, Cal, 2 and 3 are 
highly conserved in different strains of adenovirus. Ex- 
pression of the products of the ElA 12 S or 13 S gene 
inhibits LV and y IFN-inducible gene expression in stably 
transfected cells. Experiments with mutant constructs 
indicate that inhibition is mediated through the CR1 
domain. A similar inhibition is seen with cells stably ex- 
pressing both 12 S and 13 S ElA products and in 
adenovirus infected cells. Interestingly, once again the 
induction of ,8 IFN in response to double-stranded 
RNA is also inhibited in the cells expressing EIA in- 
dicating that, whether or not a common factor is involv- 
ed, more than one signal transduction pathway is af- 
fected (A. Ackrill, G.R. Stark and I.M. Kerr, un- 
published). 
The mechanisms of inhibition by terminal protein 
and ElA are not the same. There is no homology be- 
tween the proteins, and they affect different aspects of 
the response. In the case of terminal protein, the pro- 
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